SLV 313

Drug Profile

SLV 313

Alternative Names: SLV-313

Latest Information Update: 08 Mar 2010

Price : $50

At a glance

  • Originator Solvay
  • Class Antipsychotics; Piperazines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Bipolar disorders; Schizophrenia

Most Recent Events

  • 19 Nov 2008 Preclinical pharmacodynamics data presented at the 38th Annual Meeting of the Society for Neuroscience (SfN-2008) ,
  • 04 Mar 2008 SLV 313 is still in Phase I trials for Schizophrenia in USA
  • 05 Mar 2007 Phase-I clinical trials in Bipolar disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top